AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ALGN · NASDAQ · Medical - Devices

Align Technology

Builds Invisalign aligners, iTero scanners, and exocad software for digital dentistry.

$157.58

After-hours close+0.02 (+0.01%)

At close$157.56(−0.81%)

Something off on this page? Send us feedback.

Profile

Align Technology, Inc.ALGNHealth Care

Sells doctor-prescribed Invisalign clear aligners and Vivera retainers, plus iTero intraoral scanners and exocad dental CAD/CAM software. Clear aligners generate most revenue, with scanners and software linking orthodontic and restorative workflows for dental practices and laboratories.

Designs, manufactures, and markets Invisalign clear aligners and Vivera retainers for orthodontists and general dentists. The Clear Aligner segment also includes Invisalign Palatal Expander and accessories, while the smaller Systems and Services segment sells iTero intraoral scanners and licenses exocad CAD/CAM software to dental practices and laboratories.

Connects digital scans, ClinCheck treatment planning, custom aligner fabrication, monitoring, and retention in a doctor-directed workflow. iTero and exocad extend that workflow into restorative dentistry. Sales span global markets, while manufacturing and treatment-planning operations are distributed across the Americas, Europe, and Asia.

Clear aligners generate most revenue. Demand depends on dental professionals prescribing the system and patients starting largely elective treatment, while products and software must meet medical-device, privacy, and data rules across markets.

Company facts

CEOJoseph M. Hogan

ListedJan 30, 2001

ExchangeNASDAQ

HeadquartersTempe, AZ

CountryUnited States

Employees20,290

CIK0001097149

ISINUS0162551016

Key statistics

Market cap$11.29B

EPS (ttm)$5.76

P/E (ttm)27.36

ROE10.1%

P/B2.66

P/S2.73

Dividend yield—

Beta1.43vs XLV 0.64

Year to date +1.0% · Average volume (30d) 908.0K

Analysts

Price target, next 12 months$199.00+26.3%Median of 33 analysts · vs the Aug 28 close

ConsensusBuy24 of 33 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $157.58

High$235.00+49.1%

Median$199.00+26.3%

Low$188.00+19.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Jul 23, 2026	UBS	Reiterate		Neutral	$185	$189
Jul 8, 2026	BMO Capital	Initiate		Outperform		$209
Apr 24, 2026	Morgan Stanley	Reiterate		Equal Weight	$154	$188
Apr 21, 2026	Piper Sandler	Reiterate		Overweight	$220	$235
Mar 17, 2026	Barclays	Upgrade	Equal Weight	Overweight

Earnings

EPS

Estimate$2.78

ReportedDue Oct 28, 2026

Revenue

Estimate$1.01B

ReportedDue Oct 28, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jul 29, 2026Q2 FY26	$2.62	$2.64	+0.8%	$1.05B	$1.06B	+0.4%	−3.70%
Apr 29, 2026Q1 FY26	$2.26	$2.58	+14.2%	$1.02B	$1.04B	+1.8%	−1.34%
Feb 4, 2026Q4 FY25	$2.99	$3.29	+10.0%	$1.03B	$1.05B	+1.4%	+8.88%
Oct 29, 2025Q3 FY25	$2.40	$2.61	+8.8%	$976.4M	$995.7M	+2.0%	+4.94%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$979.3M	$1.01B	$995.7M	$1.05B	$1.04B	$1.06B
Gross profit	$680.1M	$708.1M	$639.2M	$688.1M	$736.6M	$688.0M
Operating income	$131.1M	$163.0M	$96.3M	$159.6M	$172.7M	$123.3M
Net income	$93.2M	$124.6M	$56.8M	$135.8M	$112.8M	$108.3M
Diluted EPS	$1.27	$1.72	$0.78	$1.89	$1.57	$1.52
Gross margin	69.5%	69.9%	64.2%	65.7%	70.8%	65.1%
Operating margin	13.4%	16.1%	9.7%	15.2%	16.6%	11.7%

Fiscal years (4-quarter sums)FY21 $3.95B · FY22 $3.73B · FY23 $3.86B · FY24 $4.00B · FY25 $4.03B

Revenue by product · FY25

Clear Aligner$3.25B · 80%

Scanners And Services$789.6M · 20%

Revenue by geography · Q2 FY26

Other International$412.4M · 39%

United States$395.2M · 37%

Switzerland$248.6M · 24%

Balance sheet, Jun 30, 2026Cash & short-term investments $1.10B · Total debt $120.8M · Total assets $6.42B · Shareholders' equity $4.23B

Dividends

No dividends on record.

Ownership

Institutions 121.01%Insiders 0.67%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 71.62M · Float 66.91M · 93.4% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	4.42M	6.17%	13F	Aug 7, 2026
Vanguard Capital Management LLC	4.40M	6.15%	13F	Aug 13, 2026
FMR LLC	4.06M	5.67%	13F	Aug 13, 2026
Capital International Investors	4.05M	5.65%	13F	Aug 12, 2026
Capital World Investors	3.42M	4.78%	13F	Aug 12, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Feb 18, 2026	John Morici	officer: EVP, CHIEF FINANCIAL OFFICER	−7,969	$189.31